JP2024102205A5 - - Google Patents

Download PDF

Info

Publication number
JP2024102205A5
JP2024102205A5 JP2024074264A JP2024074264A JP2024102205A5 JP 2024102205 A5 JP2024102205 A5 JP 2024102205A5 JP 2024074264 A JP2024074264 A JP 2024074264A JP 2024074264 A JP2024074264 A JP 2024074264A JP 2024102205 A5 JP2024102205 A5 JP 2024102205A5
Authority
JP
Japan
Prior art keywords
dose
ifnar1
inhibitor
injection device
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024074264A
Other languages
English (en)
Japanese (ja)
Other versions
JP7805393B2 (ja
JP2024102205A (ja
Filing date
Publication date
Priority claimed from JP2023562678A external-priority patent/JP7484027B2/ja
Application filed filed Critical
Publication of JP2024102205A publication Critical patent/JP2024102205A/ja
Publication of JP2024102205A5 publication Critical patent/JP2024102205A5/ja
Application granted granted Critical
Publication of JP7805393B2 publication Critical patent/JP7805393B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024074264A 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画 Active JP7805393B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US63/178,739 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US63/245,285 2021-09-17
US202163272851P 2021-10-28 2021-10-28
US63/272,851 2021-10-28
JP2023562678A JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023562678A Division JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画

Publications (3)

Publication Number Publication Date
JP2024102205A JP2024102205A (ja) 2024-07-30
JP2024102205A5 true JP2024102205A5 (https=) 2024-10-31
JP7805393B2 JP7805393B2 (ja) 2026-01-23

Family

ID=81750490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023562678A Active JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2024074264A Active JP7805393B2 (ja) 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023562678A Active JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画

Country Status (25)

Country Link
US (4) US20220340669A1 (https=)
EP (2) EP4114465B1 (https=)
JP (2) JP7484027B2 (https=)
KR (2) KR20230166134A (https=)
CN (2) CN120392997A (https=)
AU (2) AU2022260531B2 (https=)
BR (1) BR112023021761A2 (https=)
CA (1) CA3216387A1 (https=)
CL (1) CL2023003114A1 (https=)
CO (1) CO2023015498A2 (https=)
DK (1) DK4114465T5 (https=)
ES (1) ES2963757T3 (https=)
FI (1) FI4114465T3 (https=)
HR (1) HRP20231255T1 (https=)
HU (1) HUE063562T2 (https=)
IL (1) IL307748A (https=)
LT (1) LT4114465T (https=)
MX (1) MX2023012465A (https=)
PL (1) PL4114465T3 (https=)
PT (1) PT4114465T (https=)
RS (1) RS64821B1 (https=)
SI (1) SI4114465T1 (https=)
SM (1) SMT202300382T1 (https=)
TW (1) TW202317182A (https=)
WO (1) WO2022223714A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
JP2023549872A (ja) * 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
PT4192882T (pt) * 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CA2651866C (en) 2006-05-11 2014-10-28 Universiteit Gent Sialoadhesin-related compositions and methods
EP2077858A4 (en) 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
ES2542836T3 (es) 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
PT2219452E (pt) 2007-11-05 2016-01-26 Medimmune Llc Métodos de tratamento de esclerodermia
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
UA104868C2 (uk) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
AU2013274389A1 (en) * 2012-06-13 2015-01-22 Astrazeneca Ab Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
CA2995222C (en) * 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
EP3713955A4 (en) * 2018-09-18 2022-03-09 I-Mab Biopharma (Hangzhou) Co., Ltd. ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3924383A1 (en) * 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
JP2023549872A (ja) 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
PT4192882T (pt) 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Similar Documents

Publication Publication Date Title
JP2024102205A5 (https=)
US6623736B2 (en) Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP2025172841A5 (https=)
ES2963757T3 (es) Régimen de dosificación de anti-ifnar1 para inyección subcutánea
US6471961B1 (en) Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP7164530B2 (ja) Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2022160685A5 (https=)
JP2015533806A (ja) 関節リウマチの治療
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗ＩＬ－α抗体
EP4612183A1 (en) Methods for treating hand and foot dermatitis by administering an il-4r antagonist
EP4707302A2 (en) Ofatumumab for treating ms while maintaining serum igg
EP0303687B1 (en) Compositions for enhancing adcc therapy
Pitarokoili et al. Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis
WO2017221174A1 (en) Methods of treating vitiligo using interleukin-17 (il-17) antibodies
AU2019364239B2 (en) Pan-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CN115515978A (zh) 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体
KR20220104789A (ko) 류마티스 관절염의 치료를 위한 btk 억제제 및 아바타셉트의 조합물
WO2021018191A1 (zh) Il-17拮抗剂治疗自身免疫疾病的方法
JPWO2019186369A5 (https=)
MacLean et al. Immunologic therapy for relapsing-remitting multiple sclerosis
TADA et al. New Therapy in Rheumatoid Arthritis Biological DMARDs and JAK Inhibitors
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
Croasdell 35th congress of the European committee for treatment and research in multiple sclerosis (ECTRIMS)
Kaur et al. IMMUNOTHERAPY IN SPECIFIC AUTOIMMUNE DISEASES